Autres langues Oncotelic Therapeutics, Inc.

Actions

OTLC

US6283411097

Marché Fermé - OTC Markets Autres places de cotation 20:37:32 03/05/2024			Varia. 5j.	Varia. 1 janv.
0,0394 ^USD	+2,82%		-3,43%	+2,87%

12/04	Oncotelic Therapeutics, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
25/03	Oncotelic Therapeutics, Inc. annonce un lien entre le cancer et le lupus chez les patients atteints de gliomes	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.	29/04
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/04
Oncotelic Therapeutics, Inc. - Linkage of Cancer and Lupus in Gliomas Patients	26/03
Linkage of Cancer and Lupus in Gliomas Patients	25/03
Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients	25/03
Invitation to Participate in STOP-PC Clinical Trial	04/03
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	21/02
Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients	16/01
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)	22/12
Oncotelic Therapeutics Announces Opening of GMP Manufacturing Plant	18/12
Oncotelic Therapeutics Announces CEO to Discuss Proprietary AI Technology at Ibero-American Chatbot Summit	29/11
Oncotelic Therapeutics Announces CEO To Discuss Proprietary AI Technology at Ibero-American Chatbot Summit.	28/11
Earnings Flash (OTLC) ONCOTELIC THERAPEUTICS Posts Q3 Revenue $70,000	15/11
Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results	15/11
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Oncotelic Therapeutics, Inc. announces tranche update	24/10/23
Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023	28/08/23
Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023	25/08/23
Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer	23/08/23
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	18/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Oncotelic Therapeutics, Inc.

Actions

OTLC

US6283411097

Autres langues

Filtres